Cargando…

Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018

IMPORTANCE: Despite concern about harms related to long-term prescribed opioid use among individuals with chronic noncancer pain (CNCP), no study has examined whether the same patients engage in a risky pattern of use consistently for the long term. OBJECTIVE: To examine the prevalence, incidence, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Degenhardt, Louisa, Hungerford, Phillip, Nielsen, Suzanne, Bruno, Raimondo, Larance, Briony, Clare, Philip J., Dobbins, Timothy, Hall, Wayne, Cohen, Milton, Blyth, Fiona, Lintzeris, Nicholas, Farrell, Michael, Campbell, Gabrielle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035647/
https://www.ncbi.nlm.nih.gov/pubmed/33835176
http://dx.doi.org/10.1001/jamanetworkopen.2021.3059
_version_ 1783676743956037632
author Degenhardt, Louisa
Hungerford, Phillip
Nielsen, Suzanne
Bruno, Raimondo
Larance, Briony
Clare, Philip J.
Dobbins, Timothy
Hall, Wayne
Cohen, Milton
Blyth, Fiona
Lintzeris, Nicholas
Farrell, Michael
Campbell, Gabrielle
author_facet Degenhardt, Louisa
Hungerford, Phillip
Nielsen, Suzanne
Bruno, Raimondo
Larance, Briony
Clare, Philip J.
Dobbins, Timothy
Hall, Wayne
Cohen, Milton
Blyth, Fiona
Lintzeris, Nicholas
Farrell, Michael
Campbell, Gabrielle
author_sort Degenhardt, Louisa
collection PubMed
description IMPORTANCE: Despite concern about harms related to long-term prescribed opioid use among individuals with chronic noncancer pain (CNCP), no study has examined whether the same patients engage in a risky pattern of use consistently for the long term. OBJECTIVE: To examine the prevalence, incidence, persistence, and cessation of a range of opioid behaviors, indicators of extramedical use, and harm among individuals who are prescribed opioids. DESIGN, SETTING, AND PARTICIPANTS: This 5-year prospective cohort study in communities across Australia included 1514 adults who were prescribed opioids for CNCP. Data collection took place from August 2012 to December 2018, and data analysis took place from February to November 2020. EXPOSURE: Prescription opioid use. MAIN OUTCOMES AND MEASURES: High-dose opioid use (≥200 oral morphine equivalent [OME] mg/d); requesting an increase in opioid dose; requesting an early prescription renewal; tampering with opioid medication; diversion of medication to others; and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision opioid dependence. Cessation of opioid use was also assessed. RESULTS: Of the 1514 participants, 672 (44.39%) were men, the mean (SD) age was 58 (19) years, and 737 (48.68%) were unemployed. At each annual interview, approximately 1 in 8 people (10.98% [95% CI, 10.33%-11.63%] to 14.73% [95% CI, 13.98%-15.48%] at any given interview) were taking more than 200 OME mg/d; comparatively more had requested an increased dosage in the previous 3 months (8.46% [95% CI, 7.89%-9.03%] to 23.77% [95% CI, 22.82%-24.73%]); and fewer asked for an early prescription renewal (4.61% [95% CI, 4.19%-5.03%] to 13.97% [95% CI, 13.24%-14.70%]). In any given interview, between 3.06% (95% CI, 2.72%-3.40%) and 7.86% (95% CI, 7.31%-8.41%) of respondents reported tampering and between 0.47% (95% CI, 0.33%-0.60%) and 1.39% (95% CI, 1.16%-1.62%) reported diversion to others. Between 8.28% (95% CI, 7.71%-8.84%) and 13.06% (95% CI, 12.35%-13.77%) met criteria for opioid dependence at each interview. Opioid cessation increased across interviews, from year 1 (9.15% [95% CI, 8.55%-9.74%]) to year 5 (20.02% [19.14%-20.89%]). There was considerable incidence and cessation in all behaviors from 1 interview to the next: most who engaged in any of these behaviors only did so at only 1 interview. For pharmaceutical opioid dependence, between 55.26% (95% CI, 53.81%-56.71%) and 64.44% (95% CI, 62.87%-66.00%) of cases in 1 interview did not meet dependence criteria in the following interview. CONCLUSIONS AND RELEVANCE: These findings suggest considerable fluidity in opioid use, extramedical behaviors, and opioid dependence among people with CNCP. This reinforces the need for reassessment of the effectiveness and safety of prescription opioid use over time.
format Online
Article
Text
id pubmed-8035647
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-80356472021-04-27 Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018 Degenhardt, Louisa Hungerford, Phillip Nielsen, Suzanne Bruno, Raimondo Larance, Briony Clare, Philip J. Dobbins, Timothy Hall, Wayne Cohen, Milton Blyth, Fiona Lintzeris, Nicholas Farrell, Michael Campbell, Gabrielle JAMA Netw Open Original Investigation IMPORTANCE: Despite concern about harms related to long-term prescribed opioid use among individuals with chronic noncancer pain (CNCP), no study has examined whether the same patients engage in a risky pattern of use consistently for the long term. OBJECTIVE: To examine the prevalence, incidence, persistence, and cessation of a range of opioid behaviors, indicators of extramedical use, and harm among individuals who are prescribed opioids. DESIGN, SETTING, AND PARTICIPANTS: This 5-year prospective cohort study in communities across Australia included 1514 adults who were prescribed opioids for CNCP. Data collection took place from August 2012 to December 2018, and data analysis took place from February to November 2020. EXPOSURE: Prescription opioid use. MAIN OUTCOMES AND MEASURES: High-dose opioid use (≥200 oral morphine equivalent [OME] mg/d); requesting an increase in opioid dose; requesting an early prescription renewal; tampering with opioid medication; diversion of medication to others; and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision opioid dependence. Cessation of opioid use was also assessed. RESULTS: Of the 1514 participants, 672 (44.39%) were men, the mean (SD) age was 58 (19) years, and 737 (48.68%) were unemployed. At each annual interview, approximately 1 in 8 people (10.98% [95% CI, 10.33%-11.63%] to 14.73% [95% CI, 13.98%-15.48%] at any given interview) were taking more than 200 OME mg/d; comparatively more had requested an increased dosage in the previous 3 months (8.46% [95% CI, 7.89%-9.03%] to 23.77% [95% CI, 22.82%-24.73%]); and fewer asked for an early prescription renewal (4.61% [95% CI, 4.19%-5.03%] to 13.97% [95% CI, 13.24%-14.70%]). In any given interview, between 3.06% (95% CI, 2.72%-3.40%) and 7.86% (95% CI, 7.31%-8.41%) of respondents reported tampering and between 0.47% (95% CI, 0.33%-0.60%) and 1.39% (95% CI, 1.16%-1.62%) reported diversion to others. Between 8.28% (95% CI, 7.71%-8.84%) and 13.06% (95% CI, 12.35%-13.77%) met criteria for opioid dependence at each interview. Opioid cessation increased across interviews, from year 1 (9.15% [95% CI, 8.55%-9.74%]) to year 5 (20.02% [19.14%-20.89%]). There was considerable incidence and cessation in all behaviors from 1 interview to the next: most who engaged in any of these behaviors only did so at only 1 interview. For pharmaceutical opioid dependence, between 55.26% (95% CI, 53.81%-56.71%) and 64.44% (95% CI, 62.87%-66.00%) of cases in 1 interview did not meet dependence criteria in the following interview. CONCLUSIONS AND RELEVANCE: These findings suggest considerable fluidity in opioid use, extramedical behaviors, and opioid dependence among people with CNCP. This reinforces the need for reassessment of the effectiveness and safety of prescription opioid use over time. American Medical Association 2021-04-09 /pmc/articles/PMC8035647/ /pubmed/33835176 http://dx.doi.org/10.1001/jamanetworkopen.2021.3059 Text en Copyright 2021 Degenhardt L et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Degenhardt, Louisa
Hungerford, Phillip
Nielsen, Suzanne
Bruno, Raimondo
Larance, Briony
Clare, Philip J.
Dobbins, Timothy
Hall, Wayne
Cohen, Milton
Blyth, Fiona
Lintzeris, Nicholas
Farrell, Michael
Campbell, Gabrielle
Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018
title Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018
title_full Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018
title_fullStr Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018
title_full_unstemmed Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018
title_short Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018
title_sort pharmaceutical opioid use patterns and indicators of extramedical use and harm in adults with chronic noncancer pain, 2012-2018
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035647/
https://www.ncbi.nlm.nih.gov/pubmed/33835176
http://dx.doi.org/10.1001/jamanetworkopen.2021.3059
work_keys_str_mv AT degenhardtlouisa pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT hungerfordphillip pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT nielsensuzanne pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT brunoraimondo pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT larancebriony pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT clarephilipj pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT dobbinstimothy pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT hallwayne pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT cohenmilton pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT blythfiona pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT lintzerisnicholas pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT farrellmichael pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018
AT campbellgabrielle pharmaceuticalopioidusepatternsandindicatorsofextramedicaluseandharminadultswithchronicnoncancerpain20122018